Centiva Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Centiva Capital’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-50,000	Closed	-$260K	–	2552
2024 Q3	$260K	Buy	+50,000	New	+$248K	0.01%	1672
2024 Q2	–	Sell	-100	Closed	-$492	–	2594
2024 Q1	$492	Hold	100	–	–	﹤0.01%	1708
2023 Q4	$879	Sell	100 -100,000	-100%	-$819K	﹤0.01%	1717
2023 Q3	$1.15M	Buy	100,100 +50,100	+100%	+$963K	0.03%	568
2023 Q2	$1.27M	Hold	50,000	–	–	0.03%	508
2023 Q1	$1.61M	Buy	+50,000	New	+$1.56M	0.04%	473

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Centiva Capital's RVNC Position: Q1 2025 in Review

Centiva Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 14,900 shares — an estimated $45.3K sold.

Centiva Capital first reported a position in RVNC in Q1 2023 and held it in 8 quarters. The position peaked at $3.61M in Q3 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Centiva Capital reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Centiva Capital sold 14,900 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $45.3K.
Centiva Capital first reported a position in Revance Therapeutics, Inc. in Q1 2023 and held it in 8 quarters.
Centiva Capital's Revance Therapeutics, Inc. position peaked at $3.61M in Q3 2023.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Centiva Capital's 13F filing for Q1 2025, filed 15 May 2025.